INT173939

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2003
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 9
Total Number 11
Disease Relevance 5.92
Pain Relevance 1.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL6R) extracellular region (IL6R) plasma membrane (IL6R)
enzyme binding (IL6R)
Anatomy Link Frequency
spine 2
osteoclast 1
IL6R (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 12 100.00 Very High Very High Very High
cytokine 89 95.24 Very High Very High Very High
rheumatoid arthritis 369 93.92 High High
methotrexate 118 92.08 High High
Etanercept 6 78.92 Quite High
Infliximab 6 78.32 Quite High
Arthritis 50 74.04 Quite High
Inflammation 63 69.04 Quite High
Pain 9 60.08 Quite High
Inflammatory response 10 30.00 Quite Low
Disease Link Frequency Relevance Heat
Disease 96 99.52 Very High Very High Very High
Infection 75 98.84 Very High Very High Very High
Epstein-barr Virus 9 95.60 Very High Very High Very High
Mycobacterial Infection 18 95.24 Very High Very High Very High
Rheumatoid Arthritis 372 93.92 High High
Endometriosis (extended) 36 83.40 Quite High
Necrosis 21 76.72 Quite High
Cancer 25 76.36 Quite High
Juvenile Chronic Polyarthritis 29 74.04 Quite High
Rheumatic Diseases 23 71.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It remains unclear whether blocking the IL-6/IL-6R pathway directly induces the proliferation or activation of herpes group viruses such as Epstein–Barr virus (EBV).
Spec (whether) Negative_regulation (blocking) of IL-6R associated with epstein-barr virus
1) Confidence 0.11 Published 2009 Journal Mod Rheumatol Section Body Doc Link PMC2720589 Disease Relevance 1.62 Pain Relevance 0
TCZ binds to the alpha chain of both membrane-bound and soluble IL-6R, thus blocking IL-6/IL-6R signaling [2, 3].
Negative_regulation (blocking) of IL-6R
2) Confidence 0.11 Published 2009 Journal Mod Rheumatol Section Body Doc Link PMC2720589 Disease Relevance 0.79 Pain Relevance 0.35
Larger randomized controlled studies are needed to determine the effects of IL-6R blockade in erosive disease.
Negative_regulation (blockade) of IL-6R associated with disease
3) Confidence 0.06 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.69 Pain Relevance 0.26
In addition, IL-6 can form an association with sIL-6R and transmit a signal through gp130.27 Therefore, it is crucial to inhibit both mIL-6R and sIL-6R-mediated signaling to block IL-6 signaling.18 Tocilizumab is developed by grafting the complementarity determining regions of a mouse anti-human IL-6 receptor antibody onto human IgG1.28 Tocilizumab competes for both the membrane-bound (mIL-6R) and soluble (sIL-6R) forms of human IL-6 receptor, effectively blocking IL-6-mediated signal transmission in cells.18
Negative_regulation (inhibit) of mIL-6R
4) Confidence 0.02 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857613 Disease Relevance 0.51 Pain Relevance 0.10
Interestingly, increase in serum levels of E2 was associated with reduction of sIL-6R (P < 0.05) and reduction of sIL-6R was correlated with improved bone mineral density in the lumbar spine (P < 0.05).
Negative_regulation (reduction) of sIL-6R in spine
5) Confidence 0.01 Published 2003 Journal Arthritis Res Ther Section Abstract Doc Link PMC165058 Disease Relevance 0.25 Pain Relevance 0.17
Serum levels of sIL-6R, acting as an agonist to IL-6, were suppressed significantly in the HRT group after 12 and 24 months.
Negative_regulation (suppressed) of sIL-6R associated with agonist
6) Confidence 0.01 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC165058 Disease Relevance 0 Pain Relevance 0.13
HRT for 2 years resulted in an increase of the bone anabolic factor, insulin-like growth factor 1 (IGF-1) (P < 0.05) and a decrease of serum levels of soluble IL-6 receptor (sIL-6R) (P < 0.05), which is known to enhance the biological activity of IL-6, an osteoclast-stimulating and proinflammatory cytokine.
Negative_regulation (decrease) of sIL-6R in osteoclast associated with cytokine
7) Confidence 0.01 Published 2003 Journal Arthritis Res Ther Section Abstract Doc Link PMC165058 Disease Relevance 0.31 Pain Relevance 0.20
Interestingly, increase in serum levels of E2 was associated with reduction of sIL-6R (P < 0.05) and reduction of sIL-6R was correlated with improved bone mineral density in the lumbar spine (P < 0.05).
Negative_regulation (reduction) of sIL-6R in spine
8) Confidence 0.01 Published 2003 Journal Arthritis Res Ther Section Abstract Doc Link PMC165058 Disease Relevance 0.25 Pain Relevance 0.17
Increased serum levels of E2 were correlated with reduction of sIL-6R and TNF-?.
Negative_regulation (reduction) of sIL-6R
9) Confidence 0.01 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC165058 Disease Relevance 0.27 Pain Relevance 0.07
However, it is unclear if the increase of IGF-1 in this trial is caused by estrogen-mediated reduction of the IL-6/sIL-6R pathway or by effects on the GH/IGF-1 axis or by a combination of these mechanisms.
Negative_regulation (reduction) of sIL-6R
10) Confidence 0.01 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC165058 Disease Relevance 0.72 Pain Relevance 0.27
In addition, IL-6 can form an association with sIL-6R and transmit a signal through gp130.27 Therefore, it is crucial to inhibit both mIL-6R and sIL-6R-mediated signaling to block IL-6 signaling.18 Tocilizumab is developed by grafting the complementarity determining regions of a mouse anti-human IL-6 receptor antibody onto human IgG1.28 Tocilizumab competes for both the membrane-bound (mIL-6R) and soluble (sIL-6R) forms of human IL-6 receptor, effectively blocking IL-6-mediated signal transmission in cells.18
Negative_regulation (inhibit) of sIL-6R
11) Confidence 0.01 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857613 Disease Relevance 0.51 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox